Earlier this week the US Food and Drug Administration (FDA) Approved a Biologics License Application (BLA) for bevacizumab-maly, a biosimilar referencing Avastin (bevacizumab). This is the third biosimilar of bevacizumab approved in the US. A biosimilar is a medication that is almost identical to another medication. The approval of biosimilar products is regulated by the 2010 Biologics Price Competition and Innovation